The treatment of inflammatory bowel disease (IBD)—ulcerative colitis (UC) and Crohn's
disease (CD)—has evolved beyond surgery with the introduction of biologic agents …

Biologics have transformed the treatment of immune-mediated inflammatory diseases such
as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Biosimilars—biologic …

Background TNF inhibitors have improved treatment of Crohn's disease, ulcerative colitis,
spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and chronic plaque psoriasis, but …

The emergence of biologic therapies is arguably the greatest therapeutic advance in the
care of inflammatory bowel disease (IBD) to date, allowing directed treatments targeted at …

Background: CT-P13 is a biosimilar of the reference product (RP) infliximab, with
demonstrated efficacy and safety for some inflammatory arthritides. It was approved for the …

Background Biosimilars of anti‐tumour necrosis factor (TNF)‐α agents have now become
clinically available for the treatment of inflammatory bowel diseases (IBD). Aim To perform a …

The therapeutic landscape for inflammatory bowel disease [IBD] is rapidly evolving. Two
new biologic drugs, vedolizumab and ustekinumab, have recently entered the marketplace …

Biologic agents have revolutionized the care management of many life-threatening and
debilitating diseases. As patents for older biologic therapies have begun to expire, the …

Introduction New biosimilars of monoclonal antibodies are anticipated to bring significant
cost savings and increase access to treatment. The rituximab biosimilar CT-P10 has recently …

Background Limited data are available on long-term clinical outcomes regarding the switch
from Remicade® to the infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD) …